Medicines

Product Information

This site is intended for members of the public. If you are a Healthcare Professional in the UK or Ireland please click here.

AVONEX (interferon beta-1a)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

BENEPALI (etanercept)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

BYOOVIZ ▼ (ranibizumab)

Patient Information Leaflet
GB   NI

Summary of Product Characteristics
GB   NI

FAMPYRA (fampridine)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

FLIXABI (infliximab)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

IMRALDI (adalimumab)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

PLEGRIDGY (peginterferon beta-1a)

Intramuscular Patient Information Leaflet
GB   NI   Ireland

Subcutaneous Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

SPINRAZA (nusinersen sodium)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

TECFIDERA (dimethyl fumarate)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

TYSABRI (natalizumab)

Intravenous Patient Information Leaflet
GB   NI   Ireland

Subcutaneous Patient Information Leaflet
GB   NI   Ireland

Intravenous Summary of Product Characteristics
GB   NI   Ireland

Subcutaneous Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

VUMERITY (diroximel fumarate)

Patient Information Leaflet
GB   NI   Ireland

Summary of Product Characteristics
GB   NI   Ireland

European Public Assessment Report
UK & Ireland

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report them directly the via national reporting system at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store (UK). If in Ireland, report any side effects to HPRA Pharmacovigilance, Earlsfort Terrance, IRL – Dublin 2: Tel: +353 1 6764971. Website: https://www.hpra.ie; E-mail: medsafety@hpra.ie. Adverse events should also be reported to Biogen: MedInfoUKI@biogen.com UK: 0800 008 7401 (Ireland 1800 812 719) Fax: +44 (0) 1628 501010. For Biosimilar products report to: Email: medinfo.europe@biogen.com Tel: +44 (0) 203 6088622 (UK) Tel: +353 (0) 1513 3333 (Ireland). By reporting side effects you can help provide more information on the safety of the medicine.

Biogen-225545 | Date of preparation: January 2024